English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 18076/20274 (89%)
造訪人次 : 5246520      線上人數 : 1060
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34397


    標題: Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia
    作者: Chen, Pei-Yi
    Gao, Wan-Yun
    Liou, Je-Wen
    Lin, Ching-Yen
    Wu, Ming-Jiuan
    Yen, Jui-Hung
    貢獻者: Buddhist Tzu Chi Med Fdn, Hualien Tzu Chi Hosp, Ctr Med Genet
    Tzu Chi Univ, Dept Mol Biol & Human Genet
    Tzu Chi Univ, Inst Med Sci
    Tzu Chi Univ, Sch Med, Dept Biochem
    Chia Nan Univ Pharm & Sci, Dept Biotechnol
    關鍵字: dyslipidemia
    TG-rich lipoproteins
    ASCVDs
    ANGPTL3
    lipoprotein lipase
    日期: 2021
    上傳時間: 2023-11-11 11:49:34 (UTC+8)
    出版者: MDPI
    摘要: Dyslipidemia is characterized by increasing plasma levels of low-density lipoprotein-cholesterol (LDL-C), triglycerides (TGs) and TG-rich lipoproteins (TGRLs) and is a major risk factor for the development of atherosclerotic cardiovascular disorders (ASCVDs). It is important to understand the metabolic mechanisms underlying dyslipidemia to develop effective strategies against ASCVDs. Angiopoietin-like 3 (ANGPTL3), a member of the angiopoietin-like protein family exclusively synthesized in the liver, has been demonstrated to be a critical regulator of lipoprotein metabolism to inhibit lipoprotein lipase (LPL) activity. Genetic, biochemical, and clinical studies in animals and humans have shown that loss of function, inactivation, or downregulated expression of ANGPTL3 is associated with an obvious reduction in plasma levels of TGs, LDL-C, and high-density lipoprotein-cholesterol (HDL-C), atherosclerotic lesions, and the risk of cardiovascular events. Therefore, ANGPTL3 is considered an alternative target for lipid-lowering therapy. Emerging studies have focused on ANGPTL3 inhibition via antisense oligonucleotides (ASOs) and monoclonal antibody-based therapies, which have been carried out in mouse or monkey models and in human clinical studies for the management of dyslipidemia and ASCVDs. This review will summarize the current literature on the important role of ANGPTL3 in controlling lipoprotein metabolism and dyslipidemia, with an emphasis on anti-ANGPTL3 therapies as a potential strategy for the treatment of dyslipidemia and ASCVDs.
    關聯: INT J MOL SCI, v.22, n.14
    顯示於類別:[生物科技系(所)] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ijms-22-07310.pdf1590KbAdobe PDF104檢視/開啟
    index.html0KbHTML286檢視/開啟


    在CNU IR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋